Senescence-associated secretory phenotype
Human evidence is visible; an active trial pathway is not yet visible
9 human-evidence records · 0 active trials · 4,097 visible funding records · 4,074 universities
Longevity Patent Family
SENOMORPHIC COMPOSITION CONTAINING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AS ACTIVE INGREDIENT
Source-linked patent metadata for SENOMORPHIC COMPOSITION CONTAINING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AS ACTIVE INGREDIENT, including priority, record stage and longevity-topic connections.
Patent-family snapshot
Application publication visible
Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.
- Representative publication
- WO2026120578A1
- Earliest priority
- December 3, 2024
- Latest publication
- June 11, 2026
- Family publications
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Senolytics
Human evidence and active trials are visible in this field
198 human-evidence records · 12 active trials · 872 visible funding records · 7,604 universities
Organizations named in this family
Topics connected by metadata
Senescence-associated secretory phenotype88% metadata match
Senolytics88% metadata match
What this family cites
- Earlier patent references
- 0
- Scientific and other non-patent references
- 0
- Priority dates represented
- 2
References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →